Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 11, 2025, titled "Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) for Jaythari, a generic version of Deflazacort Tablets in four strengths: 6 mg, 18 mg, 30 mg, and 36 mg. Deflazacort is a corticosteroid used to treat conditions such as Duchenne muscular dystrophy and inflammatory disorders. The approval was communicated through a press release dated April 11, 2025. This adds another product to Zydus's growing portfolio of US-approved generic pharmaceuticals.
This USFDA approval allows Zydus to launch the product in the lucrative US generic drug market, which can boost its US revenue and earnings. Positive regulatory milestones like this typically support investor sentiment, though the actual revenue impact depends on market size and competition for the molecule.